10x Genomics, Inc.


SKU: TXG Category:


10x Genomics, Inc.: Initiation Of Coverage – Increased Customer Adoption of the GEM-X Platform 


10x Genomics witnessed good momentum in 2023, achieving a 20% growth in total revenue amounting to $ 619 million. The primary contributing factor of this growth was the launch of Xenium that resulted in greater than 250 instrument sales in just its first year. The company’s entry into spatial biology was successful with spatial revenue amounting to over $135 million for the year. 10x Genomics sold close to 6000 cumulative instruments worldwide, a 29% increase year-over-year. This was possible due to the successful operation of their new R&D manufacturing hub in Pleasanton that multiplied growth and allowed them to maintain cash discipline while scaling. `

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!